Literature DB >> 20120040

Pharmacokinetics of luteolin and tetra-acetyl-luteolin assayed by HPLC in rats after oral administration.

Xiujie Chen1, Lei Liu, Zhizhong Sun, Yongsheng Liu, Jiankai Xu, Sibo Liu, Bangqing Huang, Ling Ma, Zhiguo Yu, Kaishun Bi.   

Abstract

Accurate and reproducible HPLC methods were developed and validated for the determination of concentrations of luteolin (LT) and tetra-acetyl-luteolin (TALT) in rat plasma. HPLC analyses were performed on an Agilent TC-C(18) column protected by a guard Agilent Zorbax Eclipse Plus. The mobile phase for LT was a binary mixture of acetonitrile-water (40:60, v/v) containing 0.5% phosphoric acid at a flow rate of 1.0 mL/min, and that for TALT was a binary mixture of methanol-water (70 : 30, v/v) containing 0.5% glacial acetic acid at the same flow rate. The UV detection wavelength for both analytes was set at 350 nm. The calibration curve was linear over the range of 40-1800 ng/mL, the lower limit of quantitation was 40 ng/mL and the lower limit of detection was 20 ng/mL for both LT and TALT. The intra- and inter-day precision (RSD) values for all samples were within 7.9%. The concentration-time curves of LT and TALT after oral administration (30 mg/kg) were both fitted to a two-compartment model. The pharmacokinetic characteristics of TALT were better than that of LT in the maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20120040     DOI: 10.1002/bmc.1370

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  6 in total

1.  Development, Characterization, and Investigation of In Vivo Targeted Delivery Efficacy of Luteolin-Loaded, Eudragit S100-Coated mPEG-PLGA Nanoparticles.

Authors:  Xia Liu; Mengying Zhang; Yuxin Tian; Ruijia Liu; Yunfei Wang; Feifei Guo; Yanling Gong; Meixing Yan
Journal:  AAPS PharmSciTech       Date:  2022-03-29       Impact factor: 3.246

2.  Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.

Authors:  Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2013-02-07       Impact factor: 4.030

3.  Cytotoxic potential of Anisochilus carnosus (L.f.) wall and estimation of luteolin content by HPLC.

Authors:  Jaykumar Bhagat; Richard Lobo; Nimmy Kumar; Jessy Elizabeth Mathew; Aravinda Pai
Journal:  BMC Complement Altern Med       Date:  2014-10-28       Impact factor: 3.659

4.  A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.

Authors:  Kenza Mamouni; Shumin Zhang; Xin Li; Yanhua Chen; Yang Yang; Jaeah Kim; Michael G Bartlett; Ilsa M Coleman; Peter S Nelson; Omer Kucuk; Daqing Wu
Journal:  Neoplasia       Date:  2018-07-04       Impact factor: 5.715

5.  The Flavone Luteolin Suppresses SREBP-2 Expression and Post-Translational Activation in Hepatic Cells.

Authors:  Tsz Yan Wong; Shu-mei Lin; Lai K Leung
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

6.  Anti-glycation, Carbonyl Trapping and Anti-inflammatory Activities of Chrysin Derivatives.

Authors:  Seung Hwan Hwang; Hyun Yong Kim; Guanglei Zuo; Zhiqiang Wang; Jae-Yong Lee; Soon Sung Lim
Journal:  Molecules       Date:  2018-07-17       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.